

Synribo

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-888-877-0518. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Date:	
Patient's Date of Birth:	
	_
NPI#:	
Physician Office Fax:	
esting Provider NPI#•	
Phone:	
ring Provider 🛛 Same as Requesting Provider	
NPI#:	
Phone:	
2	Patient's Date of Birth:

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight:	kg	
Patient Height:	<u></u> cm	
Please indicate the place of service for th	e requested drug.	:
\Box Ambulatory Surgical	🗖 Home	Off Campus Outpatient Hospital
On Campus Outpatient Hospital	☐ Office	^D Pharmacy
What is the ICD-10 code?		

Criteria Questions:

- 1. What is the diagnosis?
- Chronic myeloid leukemia (CML), Continue to 2

, Continue to 2□ Other, please specify.

2. Is the patient currently receiving the requested medication?

□ Yes, Continue to 8

□ No, Continue to 3

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Synribo SGM 2174-A - 11/2024. CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

3. Was the diagnosis confirmed by detection of Philadelphia (Ph) chromosome or BCR::ABL gene by cytogenetic (conventional or FISH) and/or molecular (PCR) testing? ACTION REQUIRED: If Yes, attach chart note(s) or test results of cytogenetic and/or molecular testing.

□ Yes ACTION REQUIRED: Submit supporting documentation, Continue to 4

□ No, Continue to 4

Unknown, *Continue to 4*

4. Has the patient received a hematopoietic stem cell transplant (HSCT) for chronic myeloid leukemia (CML)?

 \Box Yes, Continue to 6

□ No, Continue to 5

5. What is the CML phase?

Chronic phase, *Continue to 6*

□ Accelerated phase, *Continue to 6*

□ Blast phase, *Continue to 6*

6. Did the patient experience resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) (for example, bosutinib [Bosulif], dasatinib [Sprycel], imatinib [Gleevec], nilotinib [Tasigna], ponatinib [Iclusig])? □ Yes, Continue to 7

□ No, *Continue to* 7

7. Will the requested medication be used as a single agent? □ Yes, No Further Questions □ No, No Further Questions

8. Has the patient received a hematopoietic stem cell transplant (HSCT) for chronic myeloid leukemia (CML)? \Box Yes, Continue to 10

□ No, Continue to 9

9. Was the diagnosis confirmed by detection of Philadelphia (Ph) chromosome or BCR::ABL gene by cytogenetic (conventional or FISH) and/or molecular (PCR) testing?

 \square Yes, Continue to 10

 \square No, Continue to 10

□ Unknown, Continue to 10

10. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?

□ Yes, No Further Questions

□ No, No Further Questions

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

Х

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Synribo SGM 2174-A - 11/2024. CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com